Literature DB >> 6508980

Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.

M W Teunissen, P Spoelstra, C W Koch, B Weeda, W van Duyn, A R Janssens, D D Breimer.   

Abstract

The effect of liver cirrhosis on plasma clearance and metabolite profile of i.v. administered antipyrine was studied in 23 patients with alcoholic liver cirrhosis (age 37-70 years) and 17 healthy subjects (age 28-55 years). Liver volume was also measured and was found to be larger in patients than in controls, mean values being 1.86 and 1.36 l respectively. The elimination half-life of antipyrine in patients with alcoholic liver cirrhosis was significantly longer than in the healthy subjects (P less than 0.001). Mean values were 39.9 and 10.1 h respectively. Alcoholic liver cirrhosis had no effect on the apparent volume of distribution of antipyrine, but antipyrine plasma clearance was substantially reduced in the patients. Mean clearance values (ranges) were 13.5 (9.3-22.8) ml/min in the patients and 49.3 (31.1-103) ml/min in healthy subjects. Normalization of antipyrine plasma clearance for liver volume resulted in an only slightly increased distinction between patients and healthy subjects, mean values (ranges) being 7.8 (3.3-13.0) ml min(-1) 1(-1) and 36.1 (21.9-35.9) ml min(-1) 1(-1) respectively. The cumulative renal excretion of 4-hydroxyantipyrine (OHA) and norantipyrine (NORA) was significantly lower in patients with alcoholic liver cirrhosis than in healthy subjects, as was the total recovery of antipyrine and major metabolites from urine. Mean values were 15.0, 8.4 and 41.2% of dose in the patients respectively and 24.3, 25.8 and 68.9% of dose in the control subjects. Excreted amounts of total and unconjugated 3-hydroxymethylantipyrine (HMA) and of unchanged antipyrine were the same in the two groups.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6508980      PMCID: PMC1463543          DOI: 10.1111/j.1365-2125.1984.tb02533.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  27 in total

1.  Differential effects of enzyme induction on antipyrine metabolite formation.

Authors:  M Danhof; R M Verbeek; C J van Boxtel; J K Boeijinga; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

2.  Drugs as indicators of hepatic function.

Authors:  R A Branch
Journal:  Hepatology       Date:  1982 Jan-Feb       Impact factor: 17.425

3.  Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.

Authors:  M Danhof; A van Zuilen; J K Boeijinga; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease.

Authors:  M Homeida; C J Roberts; M Halliwell; A E Read; R A Branch
Journal:  Gut       Date:  1979-07       Impact factor: 23.059

5.  Influence of sex and oral contraceptive steroids on antipyrine metabolite formation.

Authors:  M W Teunissen; A K Srivastava; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1982-08       Impact factor: 6.875

Review 6.  Influence of cigarette smoking on drug metabolism in man.

Authors:  W J Jusko
Journal:  Drug Metab Rev       Date:  1979       Impact factor: 4.518

7.  Effect of cimetidine on microsomal drug metabolism in man.

Authors:  J Puurunen; E Sotaniemi; O Pelkonen
Journal:  Eur J Clin Pharmacol       Date:  1980-08       Impact factor: 2.953

8.  3-Hydroxymethyl antipyrine excretion in urine after an oral dose of antipyrine. A reconsideration of previously published data and synthesis of a pure reference substance.

Authors:  M Danhof; M W Teunissen; D D Breimer
Journal:  Pharmacology       Date:  1982       Impact factor: 2.547

9.  Spironolactone and enzyme induction in patients with alcoholic cirrhosis.

Authors:  J P Miguet; D Vuitton; A Thebault-Lucas; C Joanne; D Dhumeaux
Journal:  Gastroenterology       Date:  1980-05       Impact factor: 22.682

10.  Differential induction of antipyrine metabolism by rifampicin.

Authors:  E L Toverud; A R Boobis; M J Brodie; S Murray; P N Bennett; V Whitmarsh; D S Davies
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

View more
  17 in total

1.  Disposition of antipyrine in patients with extensive metastatic liver disease.

Authors:  G M Robertz-Vaupel; K D Lindecken; T Edeki; C Funke; S Belwon; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients.

Authors:  D Larrey; G Babany; M Tinel; E Freneaux; G Amouyal; F Habersetzer; P Letteron; D Pessayre
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

3.  Partial metabolic clearances as determinants of the oral bioavailability of propranolol.

Authors:  T Walle; U K Walle; L S Olanoff; E C Conradi
Journal:  Br J Clin Pharmacol       Date:  1986-09       Impact factor: 4.335

4.  Research in the Division of Pharmacology.

Authors:  D D Breimer
Journal:  Pharm Weekbl Sci       Date:  1985-04-26

5.  Antipyrine clearance and metabolite formation in children with congenital adrenal hyperplasia.

Authors:  M W Teunissen; G J Bruining; B M De Jongh; E W Tenkate-Westerhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

6.  Antipyrine metabolite formation and excretion in patients with chronic renal failure.

Authors:  M W Teunissen; D Kampf; I Roots; N P Vermeulen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.

Authors:  J Posner; M Danhof; M W Teunissen; D D Breimer; P D Whiteman
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

8.  The influence of ranitidine on the pharmacokinetics and toxicity of doxorubicin in rabbits.

Authors:  N L Harris; D E Brenner; L B Anthony; J C Collins; S Halter; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Pharmacokinetics of caffeine in patients with decompensated type I and type II diabetes mellitus.

Authors:  T Zysset; H Wietholtz
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

10.  The pharmacokinetics of antipyrine and three of its metabolites in the rabbit: intravenous administration of pure metabolites.

Authors:  J V St Peter; Y Abul-Hajj; W M Awni
Journal:  Pharm Res       Date:  1991-12       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.